Chongshan Bio's Synthetic Collagen Project Secures Tens of Millions in Seed Funding
Recently,Zhejiang Chongshan Biological Products Co., Ltd., a company specializing in the research of fully functional active collagen, announced that its subsidiary for synthetic collagen projects, established under its controlling interest in June, has completed an angel financing round exceeding RMB 10 million. This round was invested by three institutions, including Beijing Meizan Investment Co., Ltd. The raised funds will be primarily used to accelerate the research and development and production of fully functional synthetic humanized collagen.
Zhejiang Chongshan Biological Products Co., Ltd. is committed to the mission of “Empowering Health with Technology.” Specializing in the research of fully functional active collagen, the company manufactures a comprehensive product line covering active collagen raw materials, medical devices, medical aesthetics and healthcare products, and 3D reagents. Recognized as a National High-Tech Enterprise and a Zhejiang Province “Specialized, Refined, Differential, and Innovative” (SRDI) Enterprise, Chongshan produces fully functional active collagen through biosynthesis and natural extraction methods. The company holds multiple Class III medical device registrations in China, possesses the world’s first patent for an implant derived from bovine Achilles tendon, and holds the first patent for soluble collagen skin boosters (water-light injections). In total, it has secured over 50 intellectual property rights, including original invention patents. Backed by an expert team of more than 30 professionals, including professors, PhDs, and master’s degree holders, the company engages in technical cooperation and research with prestigious institutions such as Tsinghua University and Zhejiang University. Currently, Chongshan Biological has established and holds a controlling interest in a subsidiary dedicated to synthetic collagen projects. Leveraging synthetic biology technologies, this subsidiary focuses on the research and production of synthetic human-derived fully functional collagen, continuously expanding its applications in tissue regeneration, wound repair, wound care, medical aesthetics, lifestyle beauty, cell culture matrices, and pure collagen matrices.
Collagen is a natural macromolecular material with high potential, boasting broad market prospects in fields such as healthcare, aesthetics, and wellness. It is projected to evolve into a major industry with an annual output value exceeding RMB 500 billion. The Chongshan Biosynthetic Collagen Project is led by General Manager Carlson Chen, an investor from Carlson International (Hong Kong) with over 20 years of experience in managing multinational teams and commercial operations, who is also responsible for this round of financing. He stated, “As a frontier representative driving disruptive innovation and interdisciplinary integration in the field of biology in the 21st century, synthetic biology has garnered significant attention from governments, academia, and industry worldwide. Synthetic collagen (SynthColTM) First proposed by Chongshan Biological, it is an iterative version of recombinant collagen. Its main difference from recombinant collagen lies in its more precise biological design and more convenient modular assembly, enabling the large-scale production of fully functional human-derived collagen through engineered methods. The product features high biomimicry, high activity, and high biocompatibility.
The establishment of the subsidiary for Chongshan’s biosynthetic collagen project marks another breakthrough and development for Zhejiang Chongshan Biological Products Co., Ltd. in the collagen field. Leveraging its parent company’s technological and industrial expertise, as well as the advantages of fully functional biosynthetic human collagen, the new company will develop more innovative, safe, and effective products to meet the demands of various sectors.